Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...

A phase 3 trial of Intellia Therapeutics’ in vivo gene editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...

For most of their lives, plants get their energy from photosynthesis. But during the seed to seedling stage, when they can't ...

The company's treatment for hereditary angioedema reduced attacks by 87% vs. placebo in a Phase 3 trial, clearing the way for ...

CRSP eyes a Q1 beat as rising Casgevy uptake, improving sales outlook and a strong Earnings ESP set the stage ahead of results.

Intellia Therapeutics has reported the first-ever phase 3 results with an in vivo gene-editing therapy, hereditary angioedema ...

Intellia Therapeutics (NTLA) shares charged up on April 27 after the company announced landmark Phase 3 results for its ...

We'll know more about the company's medium-term prospects by the end of the year.

Florida-based biotech company Soilcea developed CarriCea T1, a Carrizo orange variety that is resistant to HLB, also known as ...

Intellia Therapeutics’ CRISPR-based therapy lonvoguran ziclumeran reduced hereditary angioedema attacks by 87% in a pivotal ...

There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The ...

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...